ADMA Biologics Faces Class Action Lawsuit Over Alleged Market Deception

The complaint filed against ADMA Biologics, Inc. (NASDAQ: ADMA) centers on claims that the firm violated the Securities Exchange Act of 1934. According to the legal filing, the company allegedly misled the market by failing to disclose specific related-party transactions. Furthermore, the suit asserts that ADMA practiced channel stuffing—a tactic used to artificially boost sales figures and create a false perception of growth to shareholders.

Investors seeking to participate in the potential recovery have until August 10, 2026, to act. While the DJS Law Group is currently seeking lead plaintiffs to head the litigation, the firm notes that individual shareholders do not need to hold a lead position to qualify for any eventual settlement or judgment. Those who incurred losses during the specified class period are encouraged to reach out to the firm’s Eastchester, New York office to review their legal standing.